Chahbahadarwala

By Oncology Insights Desk Executive Summary Weight gain, altered basal metabolism, and chronic metabolic shifts are among the most persistent and distressing side effects experienced by individuals undergoing treatment for early-stage breast cancer. While historically viewed primarily as quality-of-life concerns, modern oncology increasingly recognizes metabolic dysfunction and obesity as critical drivers of adverse long-term clinical outcomes—including heightened risks of cancer recurrence, type 2 diabetes, and cardiovascular mortality. Beyond Weight Loss: How GLP-1 Receptor Agonists Are Rewriting Survival Outcomes in Non-Metastatic Breast Cancer At the ASCO Annual Meeting, landmark real-world findings led by Dr. Jasmine Sukumar revealed a compelling shift in survivorship science: non-metastatic breast cancer patients prescribed GLP-1 receptor agonists demonstrated a 95.8% five-year overall survival rate , compared to 89.5% in matched non-users. Supported by Conquer Cancer, the AS...

by: Eric W. Dolan        Creatine for Mental Health: Can a Gym Supplement Cure Major Depression? Introduction       For decades, creatine monohydrate has sat proudly on gym shelves as the undisputed king of fitness supplements. Celebrated by bodybuilders, sprinters, and endurance athletes, it had a straightforward primary job: increase physical strength, speed up muscle recovery, and maximize energy output during high-intensity training. However, neuroscientists and psychiatrists are turning their attention to a surprising new frontier for this white powder—the human brain. Recent breakthrough research published in The Canadian Journal of Psychiatry highlights that creatine monohydrate may offer powerful therapeutic potential in managing major depressive disorder (MDD). As millions around the globe seek alternative or complementary ways to manage mood disorders without overwhelming side effects, could a cheap, widely available gym supplement hold...